Sugi Predict
/ Targets
/ NTRK3
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to NTRK3 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors |
PHASE2 | RECRUITING |
| A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors |
PHASE2 | COMPLETED |
| A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer |
PHASE2 | WITHDRAWN |
| Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) |
PHASE2 | ACTIVE_NOT_RECRUITING |
| A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities |
PHASE1/PHASE2 | RECRUITING |
| A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients |
PHASE2 | RECRUITING |
| Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer |
PHASE1/PHASE2 | COMPLETED |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations |
PHASE1/PHASE2 | RECRUITING |
| Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors |
PHASE2 | RECRUITING |
| A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Phase II Study of Vandetanib in Individuals With Kidney Cancer |
PHASE2 | COMPLETED |
| Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy |
PHASE2 | COMPLETED |
| A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b |
PHASE1 | COMPLETED |
| A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations |
PHASE1 | UNKNOWN |
| AZD7451 for Recurrent Gliomas |
PHASE1 | COMPLETED |
| Study of FCN-098 in Patients With Advanced Solid Tumor |
PHASE1 | UNKNOWN |
| NTRK 1,2,3 Rearrangements in Patients With Solid Tumors |
nan | ACTIVE_NOT_RECRUITING |
| A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib |
nan | COMPLETED |
| Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene Fusion |
nan | COMPLETED |
| A Retrospective Study to Determine the Incidence of NTRK Fusions. NTRK Study |
nan | COMPLETED |
| Biomarkers in Blood and Tissue Samples From Patients With Newly Diagnosed Neuroblastoma |
nan | COMPLETED |
| Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins. |
nan | UNKNOWN |
| RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions. |
nan | ACTIVE_NOT_RECRUITING |
| Expanded Access to Provide Larotrectinib for the Treatment of Cancers With a NTRK Gene Fusion |
nan | APPROVED_FOR_MARKETING |
| Regular Exercise Improves Physical Capacity and Promotes Neurotrophins in Patients With Multiple Sclerosis |
nan | COMPLETED |
| Studying Gene Expression in Samples From Younger Patients With Neuroblastoma |
nan | COMPLETED |
| Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion in Spain (SPAINTRK) |
nan | COMPLETED |
| Association of Urine BDNF and NGF With Lower Urinary System Parameters |
nan | RECRUITING |
| Spanish Study for Molecular Characterization of Thyroid Carcinoma |
nan | ACTIVE_NOT_RECRUITING |
Related proteins — ESM-2 sequence neighbours (a NTRK3 binder may also engage these)